What is Kisqali
Approved as Treatment by the FDARibociclib, commonly known as Kisqali, is approved by the FDA for 3 uses like Postmenopause and Breast .
When to interrupt dosageThe recommended measure of Kisqali is contingent upon the ascertained condition, for example Metastatic Breast Cancer, Breast and Postmenopause. The dosage likewise vacillates as per the approach of delivery (e.g. Oral or Tablet, film coated) specified in the table beneath.
WarningsThere are 20 known major drug interactions with Kisqali.
Kisqali Novel Uses: Which Conditions Have a Clinical Trial Featuring Kisqali?94 active clinical trials are currently assessing the potential of Kisqali to provide therapeutic benefit in Metastatic Breast Cancer, Postmenopausal Women and Breast Diseases.
Kisqali Reviews: What are patients saying about Kisqali?
Patient Q&A Section about kisqali
What is the drug Kisqali used for?
"KISQALI® is a prescription medicine that is used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer). The cancer must have gotten worse or has spread to other parts of the body (metastatic) in order for KISQALI® to be prescribed. It is usually taken in combination with an aromatase inhibitor as the first hormonal based therapy for postmenopausal women or with fulvestrant." - Anonymous Online Contributor
Is Kisqali a chemotherapy?
"KISQALI is not a chemotherapeutic drug, but a targeted therapy that inhibits substances that contribute to cancer cell growth. Targeted therapies can harm both cancerous and healthy cells." - Anonymous Online Contributor
How much longer do you live on Kisqali?
"The median overall survival rate for those taking KISQALI was not reached at the 39 month check-in, as opposed to the 40 months check-in for those taking placebo. Results at the 56-month observational check-in showed that the median overall survival rate for those taking KISQALI in combination with fulvestrant was 53.7 months, as opposed to 41.5 months for those taking placebo and fulvestrant." - Anonymous Online Contributor